Could A Halted Sjögren Trial Alter The Investment Case For argenx Stock?

• argenx announced that it has permanently stopped the Phase 3 UNITY trial of Vyvgart Hytrulo in moderate to severe Sjögren's disease after an independent committee concluded the study could not meet its primary endpoint, although the safety profile remained consistent with prior experience.
• The UNITY setback removes a potential new autoimmune indication for Vyvgart, which had represented a possible extension of argenx's core commercial franchise and potential future revenue breadth.
• Next, the focus will be on how argenx's investment narrative absorbs the lost Sjögren's opportunity from UNITY while relying more on other programs.

Spot 618 high quality undiscovered gems that, like argenx, are working on high-impact autoimmune and immunology therapies yet still fly under most investors' radar.

argenx Investment Narrative Recap

To own argenx, you need to believe the business can turn VYVGART and its FcRn know how into a multi indication autoimmune franchise, then gradually balance that with a broader pipeline. The UNITY stop hurts that expansion story but does not change the near term focus on gMG and CIDP execution, pricing pressure, and competition as the key drivers.

The biggest swing factor over the next year is how quickly VYVGART Hytrulo and new indications translate into volume and operating leverage, while gross to net headwinds and rebate creep are managed. The main risk is concentration in one product, where any competitive or reimbursement shock would affect both earnings and reinvestment capacity.

Against the UNITY disappointment, the recent FB102 Phase 2 win in celiac disease keeps argenx’s pipeline relevant to the autoimmune thesis. The study hit its histology based primary endpoint, with intestinal tissue data and symptom readouts broadly aligned, and safety in line with prior experience.

This matters for catalysts because FB102 now appears positioned as a potential second growth pillar if Phase 3 results are consistent with the Phase 2 effect. That could gradually lessen dependence on VYVGART. It also tests argenx’s ability to integrate acquisitions and move an externally sourced asset from mid stage data into a larger, more expensive late stage program without stretching spending discipline.

argenx's current analyst narrative points to revenues of $10.3b and earnings of $3.5b by 2029, based on an assumed 24.5% yearly revenue growth rate and an earnings increase of about $1.8b from current earnings of $1.7b.

Uncover why argenx's fair value indicates a 42% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

One alternate, more optimistic angle treats FB102 as the key swing factor for argenx after the UNITY setback. Before this news, the most bullish analysts were penciling in about $11.1b of revenue and $3.7b of earnings by 2029, and using that to justify a higher price target. Those views have not yet absorbed this week’s data. Use them as one reference point, then compare several narratives and decide which assumptions feel realistic to you.

Explore 5 other argenx fair value estimates, including one that suggests as much as 241% upside from the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

• A great starting point for your argenx research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for argenx. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to consider argenx's overall financial health at a glance.

Looking for more argenx style investment ideas?

If the argenx story has you thinking about what else might be hiding in plain sight, the Simply Wall St Screener can help you widen the search without losing focus on quality and risk.

• For investors who want potential mispricings with solid fundamentals behind them, scan through 174 high quality undervalued stocks that already combine healthy finances with attractive valuations.
• If capital preservation comes first for you, filter for 222 resilient stocks with low risk scores that aim to keep downside in check while still leaving room for sensible upside.
• When balance sheet strength is non negotiable, start with a list of solid balance sheet and fundamentals (204 results) that also pair robust finances with underlying business quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com